Key stats
About First Trust Nasdaq Pharmaceuticals ETF
Home page
Inception date
Sep 20, 2016
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
First Trust Advisors LP
Distributor
First Trust Portfolios LP
ISIN
US33738R8372
FTXH holds a concentrated basket of 30 highly liquid pharmaceutical stocks weighted according to various factors. While many funds perform a basic liquidity screen as part of their index construction and rebalancing, FTXH goes beyond the basic screen and uses liquidity for selection. The 30 most liquid pharmaceutical stocks in the US are chosen for inclusion in the index as determined by 3-month average daily traded volume. The selected constituents are then ranked and weighted on three different factors: 1) strong growth, as exhibited by 3-, 6-, 9-, and 12-month average price returns, 2) attractive value, evaluated by cash-flow-to-price, and 3) low volatility, based on historical price fluctuations. Single security weights are capped at 8%. The index is rebalanced quarterly and reconstituted annually.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.85%
Health Technology93.58%
Commercial Services4.85%
Health Services0.82%
Distribution Services0.60%
Bonds, Cash & Other0.15%
Cash0.15%
Stock breakdown by region
North America94.86%
Europe5.14%
Latin America0.00%
Asia0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
FTXH invests in stocks. The fund's major sectors are Health Technology, with 93.58% stocks, and Commercial Services, with 4.85% of the basket. The assets are mostly located in the North America region.
FTXH top holdings are Johnson & Johnson and AbbVie, Inc., occupying 8.07% and 7.57% of the portfolio correspondingly.
FTXH last dividends amounted to 0.09 USD. The quarter before, the issuer paid 0.10 USD in dividends, which shows a 11.21% decrease.
FTXH assets under management is 15.18 M USD. It's risen 4.47% over the last month.
FTXH fund flows account for −3.07 M USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Yes, FTXH pays dividends to its holders with the dividend yield of 1.59%. The last dividend (Jun 30, 2025) amounted to 0.09 USD. The dividends are paid quarterly.
FTXH shares are issued by AJM Ventures LLC under the brand First Trust. The ETF was launched on Sep 20, 2016, and its management style is Passive.
FTXH expense ratio is 0.60% meaning you'd have to pay 0.60% of your investment to help manage the fund.
FTXH follows the Nasdaq US Smart Pharmaceuticals Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
FTXH invests in stocks.
FTXH price has risen by 7.60% over the last month, and its yearly performance shows a −6.28% decrease. See more dynamics on FTXH price chart.
NAV returns, another gauge of an ETF dynamics, showed a 9.16% increase in three-month performance and has decreased by −4.36% in a year.
NAV returns, another gauge of an ETF dynamics, showed a 9.16% increase in three-month performance and has decreased by −4.36% in a year.
FTXH trades at a premium (0.03%) meaning the ETF is trading at a higher price than the calculated NAV.